Interview with Kim Seung-Ho, Chairman, Boryung Pharmaceutical
Boryung has a very interesting history, starting as a pharmacy in Seoul and going on to become one of the top 10 pharmaceutical companies in South Korea. What can you…
Address: 5F, DaeHan Bldg 201-6, Guui-Dong, Kwangjin-Gu Seoul,Republic of Korea
Tel: +82 2 456 3043
KRPIA represents Republic of Korean Research-based Pharmaceutical Industry Association. KRPIA is the association of research-based companies which deliver innovative new medicines to the market through incessant research endeavors. KRPIA was established in March 1999, consisting of 24 multinational research-based pharmaceutical companies operating in Republic of Korea. At present, KRPIA has 28 member companies which are taking the lead in the world’s pharmaceutical market. KRPIA believes ‘New Medicines, New Hope’ so it is devoted to providing new innovative drugs in Republic of Korea and disseminating pharmaceutical-related information. KRPIA members have the best possible conditions to research, develop, market and inform about their pharmaceuticals, thus ensuring broad and fast access for patients to the best medical treatment. The value of research based medicines for the Republic of Korean society is visible and recognized in a health system with the patient as priority. The Republic of Korean Research-based Pharmaceutical Industry Association is perceived as a responsible partner that makes a valuable contribution to society.Mision: Promote the development and prompt introduction of innovative new pharmaceuticals Enhance the ethical standards of the pharmaceutical industry Strengthen the pharmaceutical industry’s contribution to the advancement of public health Effectively disseminate pharmaceutical-related information and contribute to medical treatment for patients and public health promotion
Boryung has a very interesting history, starting as a pharmacy in Seoul and going on to become one of the top 10 pharmaceutical companies in South Korea. What can you…
What drove you to make the move from the academia to the business sector when you decided to establish Medy-Tox in 2000? I founded Medy-tox in the year 2000, in…
What are the origins of Lundbeck in Korea and your involvement in its establishment? I joined Lundbeck just before it was officially established in Korea in April 2002. We started…
Though you have recently been appointed as President of KRIBB, your history with the institute goes quite far back. Could you please briefly explain the role it plays within South…
Could you please introduce Shinpoong, which you founded in 1962, and mention the main milestones of this unique company in the Korean pharmaceutical industry? I founded Shinpoong in a very…
Novartis’ Head Office in Basel, Switzerland as well as several prior international assignments in Asia and Europe. What do you find as the most interesting particularities of the pharmaceutical sector…
Please introduce the Korean Food and Drug Administration (KFDA) and its main health-related responsibilities within the Korean government… The KFDA’s main duty is to cooperate and support with domestic and…
How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the…
You have a very long track record working with Novo Nordisk in Asia. What is your perspective on the Diabetes explosion that has been taking place in this part of…
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector…
You are one of the foreign multinational directors with most time in the Korean pharmaceutical industry, since 2003. What is your assessment of the direction the market has taken in…
What is KHIDI’s role in supporting the development of the Korean health industry? KHIDI performs three major roles in supporting the Korean health industry, which includes pharmaceuticals, medical devices, cosmetics,…
See our Cookie Privacy Policy Here
